| Sep 9 |
Three Things To Know To Build A Dividend Portfolio For Passive Income
|
| Sep 8 |
Johnson & Johnson (JNJ): A Magic Formula Stock You Should Pay Attention To
|
| Sep 8 |
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
|
| Sep 6 |
Dell, CoStar, PayPal And A Major Health Care Stock On CNBC's 'Final Trades'
|
| Sep 6 |
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
|
| Sep 6 |
Judge orders J&J to pay Auris investors more than $1B for merger violations
|
| Sep 5 |
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
|
| Sep 5 |
Johnson & Johnson Raises Talc Settlement Offer to $9B, Moves Closer to Settlement Victory
|
| Sep 5 |
Cigna to offer biosimilar to J&J’s arthritis drug Stelara at $0 out-of-pocket
|
| Sep 5 |
Johnson & Johnson (JNJ) Wells Fargo 2024 Healthcare Conference (Transcript)
|
